Insmed, Inc. (NASDAQ:INSM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have received a consensus rating of “Moderate Buy” from the twenty-one analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $173.2941.

Several research firms recently issued reports on INSM. Mizuho set a $196.00 target price on Insmed in a research note on Wednesday. TD Cowen raised their price objective on shares of Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Morgan Stanley raised their price objective on shares of Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. William Blair assumed coverage on shares of Insmed in a report on Wednesday, August 20th. They issued an “outperform” rating for the company. Finally, Bank of America raised their price objective on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a report on Monday, October 27th.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO William Lewis sold 6,865 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company’s stock, valued at $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 152,657 shares of company stock valued at $21,442,198 over the last ninety days. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after purchasing an additional 49,149 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after purchasing an additional 219,131 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Insmed by 3.0% during the second quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after purchasing an additional 97,073 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Insmed by 2.5% during the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after purchasing an additional 59,952 shares during the last quarter.

Insmed Stock Down 2.4%

NASDAQ INSM opened at $189.60 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a market capitalization of $40.08 billion, a PE ratio of -33.20 and a beta of 1.03. Insmed has a 1 year low of $60.40 and a 1 year high of $197.08. The business’s 50-day moving average is $152.02 and its 200 day moving average is $112.67.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Insmed will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.